The high VAF of 73.2% for the TP53 mutation (tumor cell content 30%) observed in the ovarian carcinoma tissue is consistent with a heterozygous loss of TP53 in this tissue and indicates copy-number gain. This evidence concerns the gene TP53 and neoplasm.